A Study on Bioequivalence of Cabergoline Tablets in Human Body

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

February 3, 2026

Study Completion Date

May 6, 2026

Conditions

Hyperprolactinemia

Interventions

DRUG

Cabergoline tablets test formulation

Single oral administration

DRUG

Cabergoline tablets reference formulation

Single oral administration

Trial Locations (1)

RECRUITING

Zhejiang Xiaoshan Hospital, Hangzhou

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY